Recently, first-line therapies, such as lenvatinib, have shown inhibition of FGF pathways in patients with HCC [34], however, the specificity of the drug against the FGF19–FGFR4 signaling pathway stays unclear [35]. This evidence concerns the gene FGF19 and hepatocellular carcinoma.